| 崔 珺,朱红青,刘凌泉,唐宗毅,陈 凡,郑 敏.不同剂量硼替佐米联合地塞米松对多发性骨髓瘤T细胞亚群及血清C反应蛋白、β2-微球蛋白的影响[J].,2020,(9):1720-1723 |
| 不同剂量硼替佐米联合地塞米松对多发性骨髓瘤T细胞亚群及血清C反应蛋白、β2-微球蛋白的影响 |
| Effects of Different Doses of Bortezomib Combined with Dexamethasone on T Cell Subsets, Serum C-reactive Protein and β2-microglobulin in Multiple Myeloma |
| 投稿时间：2019-12-05 修订日期：2019-12-28 |
| DOI：10.13241/j.cnki.pmb.2020.09.025 |
| 中文关键词: 剂量 硼替佐米 地塞米松 多发性骨髓瘤 T细胞亚群 C反应蛋白 β2-微球蛋白 |
| 英文关键词: Different doses Bortezomib Dexamethasone Multiple myeloma T cell subsets C-reactive protein β2-microglobulin |
| 基金项目:安徽省科技攻关基金资助项目(150104114) |
|
| 摘要点击次数: 642 |
| 全文下载次数: 344 |
| 中文摘要: |
| 摘要 目的：探讨不同剂量硼替佐米联合地塞米松对多发性骨髓瘤（MM）T细胞亚群及血清C反应蛋白（CRP）、β2-微球蛋白（β2-MG）的影响。方法：选取2010年1月~2019年8月期间皖南医学院附属马鞍山中心医院收治的52例MM患者以及南京中医药大学附属泰州医院收治的28例MM患者，共计纳入患者例数80例。根据随机数字表法分为A组（n=40，给予1.3 mg/m2硼替佐米联合地塞米松治疗）和B组（n=40，给予1.6 mg/m2硼替佐米联合地塞米松治疗），比较两组患者的疗效、T细胞亚群、血清CRP、β2-MG水平，记录两组治疗期间不良反应情况。结果：两组临床总有效率比较差异无统计学意义（P>0.05）。两组治疗5个疗程后CD3+CD4+、CD3+CD4+/CD3+CD8+均升高，且B组高于A组（P<0.05）；CD3+CD8+下降，且B组低于A组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。两组治疗5个疗程后β2-MG、CRP均下降，且B组低于A组（P<0.05）。结论：MM 患者采用1.6 mg/m2硼替佐米或者1.3 mg/m2硼替佐米联合地塞米松治疗，可获得相当的疗效及安全性，但1.6 mg/m22硼替佐米联合地塞米松治疗可更好地改善患者T细胞亚群及血清CRP、β2-MG水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of different doses of bortezomib combined with dexamethasone on T cell subsets, serum C-reactive protein (CRP) and β2-microglobulin (β2-mg) in multiple myeloma (MM). Methods: From January 2010 to August 2019, 52 MM patients from Ma'anshan Central Hospital Affiliated to Wannan Medical College and 28 MM patients from Taizhou Medical College Affiliated to Nanjing University of Traditional Chinese Medicine were enrolled in this study, a total of 80 patients were included. They were divided into group A (n=40, 1.3 mg/m2 bortezomib and dexamethasone treatment ) and group B (n=40, 1.6 mg/m2 bortezomib and dexamethasone treatment) according to the method of digital table. The curative effect, T cell subsets, serum CRP, β2-MG of the two groups were compared, and the adverse reactions during the treatment were recorded. Results: There was no significant difference between the two groups (P>0.05). CD3+CD4+, CD3+CD4+/CD3+CD8+ increased in both groups at 5 courses after treatment, and those in group B were higher than those in group A (P<0.05). CD3+CD8+ decreased, and that in group B was lower than that in group A (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The serum CRP and β2-MG levels in the two groups decreased at 5 courses after treatment, and those in group B were lower than those in group A (P<0.05). Conclusion: In MM patients, 1.6 mg/m2 bortezomib or 1.3 mg/m2 bortezomib combined with dexamethasone treatment can achieve considerable efficacy and safety, but 1.6 mg/m2 bortezomib combined with dexamethasone treatment can better improve T cell subsets and serum CRP, β2-MG levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
